Upstream Bio (UPB) Stock Price, News & Analysis

Company Overview

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

Key Stats

• Today's Range: $8.53 to $9.40
• 50-Day Range: $6.07 to $10.15
• 52-Week Range: $5.14 to $29.46
• Volume: 324,835 shs
• Average Volume: 328,210 shs
• Market Capitalization: $468.70 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $56.50
• Consensus Rating: Buy

UPB Stock Analysis - Frequently Asked Questions

How have UPB shares performed this year?

Upstream Bio's stock was trading at $16.44 at the beginning of the year. Since then, UPB stock has decreased by 46.9% and is now trading at $8.73.
View the best growth stocks for 2025 here.

How were Upstream Bio's earnings last quarter?

Upstream Bio, Inc. (NASDAQ:UPB) released its earnings results on Tuesday, May, 6th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by $0.02. The company had revenue of $0.57 million for the quarter, compared to analysts' expectations of $0.71 million.

When did Upstream Bio IPO?

Upstream Bio (UPB) raised $200 million in an IPO on Friday, October 11th 2024. The company issued 12,500,000 shares at $15.00-$17.00 per share. JPMorgan, TD Cowen, Piper Sandler and William Blair served as the underwriters for the IPO.

When did Upstream Bio's lock-up period expire?

Upstream Bio's lock-up period expired on Wednesday, April 9th. Upstream Bio had issued 15,000,000 shares in its initial public offering on October 11th. The total size of the offering was $255,000,000 based on an initial share price of $17.00. Since the expiration of Upstream Bio's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.

Who are Upstream Bio's major shareholders?

Upstream Bio's top institutional investors include Alps Advisors Inc. (0.07%), Rhumbline Advisers (0.02%), XTX Topco Ltd (0.02%) and New York State Common Retirement Fund (0.01%). Insiders that own company stock include Erez Chimovits and Ai Upstream Llc.
View institutional ownership trends.

How do I buy shares of Upstream Bio?

Shares of UPB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/06/2025
• Today: 5/09/2025
• Next Earnings (Estimated): 6/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:UPB
• Previous Symbol: NASDAQ:UPB
• CIK: 2022626
• Web: upstreambio.com
• Phone: (781) 208-2466
• Fax: N/A
• Employees: 38
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $56.50
• High Stock Price Target: $75.00
• Low Stock Price Target: $38.00
• Potential Upside/Downside: +539.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $2.37 million
• Price / Sales: 200.03
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 53,689,000
• Free Float: N/A
• Market Cap: $474.07 million
• Optionable: N/A
• Beta: N/A